SCHEMBL6024136

SCHEMBL6024136

CSc1cccc(SC)c1OC(=O)C1c2ccccc2N(c2ccccc2)c2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 6/20 0.33
KMT2A Q03164 5/20 0.33
LMNA P02545 3/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
PKM P14618 3/20 0.33
NLRP1 Q9C000 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
EGFR P00533 1/20 0.32
SRC P12931 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023539 0.77 HDAC4 (0.47) L3MBTL1MAPTKMT2ALMNAHDAC4
SCHEMBL6883436 0.73 MAPT (0.35) ALDH1A1L3MBTL1MAPTKMT2ALMNA
SCHEMBL6024855 0.72 MAPT (0.34) MAPTKDM4EHTT
SCHEMBL6024230 0.71 HDAC4 (0.42) ALDH1A1HPGDMAPTKMT2ALMNA
SCHEMBL6024543 0.70 MAPT (0.36) ALDH1A1HPGDL3MBTL1MAPTCYP1A2
SCHEMBL496708 0.68 EGFR (0.38) ALDH1A1HPGDL3MBTL1KMT2ALMNA
SCHEMBL6254107 0.68 HDAC4 (0.51) ALDH1A1HPGDL3MBTL1MAPTKMT2A
SCHEMBL7787087 0.68 HDAC4 (0.51) ALDH1A1L3MBTL1MAPTKMT2ALMNA
SCHEMBL38664478 0.68 HDAC4 (0.51) ALDH1A1HPGDL3MBTL1MAPTKMT2A
SCHEMBL7043794 0.68 PPIA (0.34) KMT2ALMNAHDAC4HDAC7HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1353908-B1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN INC (US) 2006-03-08 EP disclosed
US-6410732-B2 FORMATION OF BOND BETWEEN NITROGEN ATOM OF ACRIDAN RING AND CARBON ATOM OF ANOTHER AROMATIC OR HETEROAROMATIC RING COMPOUND; ASSAYS FOR PEROXIDASE ENZYMES AND ENZYME INHIBITORS AND IN ASSAYS EMPLOYING ENZYME-LABELED SPECIFIC BINDING PAIRS LUMIGEN, INC. 2002-06-25 US disclosed
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives LUMIGEN, INC. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives ALDH3A1, AADAC, SPR ALDH1A1 64/4885HPGD 318/4885L3MBTL1 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.